The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Susvimo for treating neovascular age-related macular degeneration (nAMD). This new treatment offers an alternative to standard monthly eye injections for patients. Susvimo utilizes a refillable implant called Contivue, which continuously delivers medication directly into the eye. Clinical studies, including Archway, LADDER, and Portal, demonstrated that Susvimo maintained vision equivalent to current monthly injections. With this implant, patients may only require two treatments per year, reducing the need for frequent clinic visits. nAMD is a significant cause of blindness in individuals over 60, affecting millions in the European Union. The Contivue implant system involves a one-time surgical procedure for insertion, along with ancillary devices for filling, refilling, and removal. Susvimo contains a customized formulation of ranibizumab, a VEGF inhibitor. Roche is exploring other molecules for potential use with the Port Delivery Platform to enhance efficacy and durability. The final decision on Susvimo's approval is expected from the European Commission soon.